Obesity Treatments News 4 November 2025

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

As of the session on 10 December 2025, Pfizer Inc. (NYSE: PFE) is trading around $25.5 per share, up modestly on the day and still far below its 2021 peak. The stock now combines a high dividend yield of roughly

10 December 2025

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after

9 December 2025

Analyst Forecasts · Biotechnology · NASDAQ:GPCR · Obesity Treatments · Pharmaceutical Industry · Stock News

Structure Therapeutics (NASDAQ: GPCR) Stock Explodes on Obesity Pill Data and $500M Offering: Latest News and Forecasts as of December 9, 2025

Snapshot: Where Structure Therapeutics Stock Stands Today Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly moved from niche obesity biotech to front‑page market story. As of December 9, 2025, GPCR is trading around $69.98, up roughly 102% in a single session

9 December 2025

Biotech News · Financial Forecasts · Investment Analysis · NASDAQ:GPCR · Obesity Treatments · Stock Market

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences Ltd. (NASDAQ: WVE) just delivered one of the wildest biotech moves of 2025. On Monday, December 8, 2025, the stock rocketed after the company reported positive Phase 1 obesity drug data for WVE‑007 and simultaneously launched a

9 December 2025

Biotech · Investing · NASDAQ:WVE · Obesity Treatments · Pharmaceutical News · Stock Market

Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk (NYSE: NVO) shares are trying to stabilise after a bruising November as fresh obesity‑drug data, a higher‑dose Wegovy filing and new analyst calls collide with lingering worries about growth and competition. 1. How Novo Nordisk stock is trading

28 November 2025

Analyst Ratings · Investment News · NYSE:NVO · Obesity Treatments · Pharma Industry · Stock Market

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted

17 November 2025

Biotechnology · Healthcare Industry · Mergers & Acquisitions · NASDAQ:MTSR · NYSE:PFE · Obesity Treatments · Pharma News

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Key takeaways What happened (Nov. 7–8) Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right (CVR) of up to $20.65 per share, valuing the biotech at up to $10 billion.

8 November 2025

Business News · Healthcare Industry · Mergers & Acquisitions · Obesity Treatments · Pharmaceuticals

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Q3 Earnings Beat and Raised Outlook Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensus

4 November 2025

Drug Development · Earnings Reports · Market Analysis · NYSE:PFE · Obesity Treatments · Pharmaceuticals

Obesity Treatments News 4 November 2025 - 10 December 2025